COR2ED Medical Education

COR2ED Medical Education: Dr Homa K. Ahmadzia (Maternal-Fetal Medicine specialist and Assistant Professor in the Department of Obstetrics and Gynecology at George Washington University hospital, USA) and Dr Jarmila A. Zdanowicz (Senior Consultant in Obstetrics and Gynecology, Clinical Head Maternity Unit, Fellow in Feto-Maternal Medicine, Department of Obstetrics and Gynecology, Bern University Hospital, Switzerland), discuss severe postpartum haemorrhage (also called PPH).

To set the scene, they explain important definitions and real-world incidence, in particular in higher resourced and less resourced countries. What is the difference between non-severe and severe PPH? What specialities are involved? And what are the consequences when PPH is not treated correctly? Additionally, Dr Ahmadzia and Dr Zdanowicz consider who is at risk, what measures can be used to diagnose, and the importance of prevention as well as treatment.

COR2ED Medical Education: Prof. Dr Amit Singal, Gastroenterologist and Hepatologist at UT Southwestern Medical Center, USA and Prof. Dr Jeroen Dekervel, GI Oncologist at UZ Leuven, Belgium, discuss the new era in treating patients with advanced HCC, focusing on treatment selection and the right time to switch to 2^nd line therapy.

In this podcast, the experts give an overview of the current 1^st and 2^nd line systemic treatment options and sequences for patients with advanced HCC by looking into the results from different clinical trials and current guidelines. They also shine a light on the differences in approved 2^nd line systemic therapies between Europe and USA.

The experts present their approach in making the decision to switch to 2^nd line therapy, thereby taking toxicity, liver function and disease progression into account. They also discuss the need for comparative effectiveness data to determine the optimal 2^nd line therapy.

 

COR2ED Medical Education: In this final episode, the experts discuss two patient case studies with oral SERDs (oral selective estrogen receptor degraders) and a novel therapy for ER+/HER2- advanced or metastatic breast cancer. Each patient presents unique and rare situations that shed light on the challenges confronting healthcare professionals and patients alike. They discuss the most up-to-date data and strategies for optimising treatment selection in each individual case.

This podcast is a conversation between two independent experts: Dr. Rena Callahan an Associate Clinical Professor of Hematology Oncology at University of California, Los Angeles David Geffen School of Medicine and Dr. Shaheenah Dawood, a consultant medical oncologist and professor of oncology at Mediclinic City Hospital, United Arab Emirates, Dubai.

COR2ED Medical Education: In this podcast episode, Prof Dimitrios Tsakiris (Haematologist, Basel University, Switzerland) and Assoc. Prof. Michael Nagler (Haematologist, Inselspital University Hospital, Bern, Switzerland) discuss when to monitor anticoagulation in clinical practice, covering both the technical aspects and the clinical usefulness. 

The two experts discussed when monitoring of direct oral anticoagulants (DOACs) is necessary for acute situations like bleeding, surgery, and thrombolysis, while recognizing its limitations.   They also discuss how to differentiate routine monitoring from critical drug level assessments, exploring the impact on clinical decisions and patient care.  In addition, they discuss the benefits of anti-Xa assays for anticoagulation monitoring, including potential standardisation and shifting from traditional assays for unfractionated heparin.

This podcast is the first episode in a series of four podcasts on thrombosis in various clinical situations.

COR2ED Medical Education: This podcast episode provides an introduction to molecular testing in the diagnosis and treatment of cancer.  Prof. David Hong from MD Anderson Cancer Center, Houston, Texas, USA and Dr Tracy Stockley from the University Health Network, Toronto, Canada discuss optimal testing strategies to identify actionable mutations.

The experts discuss genetic testing and why identifying genetic alterations is a critical step to achieving optimal patient care. They share their multidisciplinary perspectives on when to use molecular profiling and which testing methodologies should be used to identify genetic alterations to inform treatment decisions with targeted therapies throughout the patient journey.

COR2ED Medical Education: Dr. Rena Callahan an Associate Clinical Professor of Hematology Oncology at University of California, Los Angeles David Geffen School of Medicine and Dr. Shaheenah Dawood, a consultant medical oncologist and professor of oncology at Mediclinic City Hospital, United Arab Emirates, Dubai discuss oral SERDs, a novel therapy for ER+/HER2- advanced or metastatic breast cancer.

In this podcast, the experts deep-dive into two patient case studies of ER+/HER2- metastatic breast cancer, discussing the intricacies of treatment selection and sequencing to maximise outcomes, current data, and what to consider when adjusting dosage or switching treatments.

COR2ED Medical Education: This podcast series consists of two episodes where expert oncologists Dr Sam Klempner (Massachusetts General Hospital, USA) and Dr Lizzy Smyth (Oxford University Hospitals NHS Foundation Trust, UK) discuss patient cases focusing on gastric and gastroesophageal junction cancer. 

In the second episode, Dr Klempner presents a case of a patient with advanced/metastatic gastric cancer.  The two experts discuss biomarker testing such as MMR, HER2, PD-1 and CLDN 18.2. They also discuss treatment options, CPS scoring and test selection plus recent clinical trial data that are practice changing.

COR2ED Medical Education: This podcast series consists of two episodes where expert oncologists Dr Sam Klempner (Massachusetts General Hospital, USA) and Dr Lizzy Smyth (Oxford University Hospitals NHS Foundation Trust, UK) discuss patient cases focusing on gastric and gastroesophageal junction cancer. 

In this first episode, Dr Smyth presents a case of operable localised gastric cancer.  The two experts discuss the importance of MMR biomarker testing And CROSS VS FLOT management approaches. They refer to data from recent clinical trials in upper gastrointestinal cancer such as MATTERHORN, NEONIPIGA, INFINITY, KEYNOTE-811 and KEYNOTE-585 and how data might impact clinical management. 

COR2ED Medical Education: Robert Mitchell-Thain, CEO of the PBC Foundation, Edinburgh, UK and Kath Houghton, Autoimmune Specialist Nurse, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK, discuss their ‘Primary Biliary Cholangitis (PBC) highlights from EASL 2023’ in this podcast.

Their discussion covers the relationship between initial symptoms and disease trajectory, the association of biochemical control and outcomes in PBC, and the impact and assessment of patient reported outcomes.

COR2ED Medical Education: Prof. Gideon Hirschfield, Professor of Medicine, Division of Gastroenterology, University of Toronto, Canada and Dr Emma Culver, Consultant Hepatologist and Honorary Senior Lecturer at the John Radcliffe Hospital and University of Oxford, UK discuss their ‘Primary Biliary Cholangitis (PBC) highlights from EASL 2023’ in this podcast.

Their discussion focuses on cancer risk associated with PBC; liver stiffness and prognosis; and outcomes and response prediction in second-line therapy.